GEMi011-A-1

GN-JY02-02-011(PSEN1-exon9-KO)

The cell line is not validated yet.

General

Cell Line

hPSCreg name GEMi011-A-1
Cite as:
GEMi011-A-1
Alternative name(s)
GN-JY02-02-011(PSEN1-exon9-KO)
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 20th December 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Shanghai Gemple Biotech Co.,Ltd (GEM)
Owner Shanghai Gemple Biotech Co.,Ltd (GEM)

External Databases

BioSamples SAMEA117551077

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex female
Ethnicity Chinese Han

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Family history Not available
Is the medical history available upon request? No
Is clinical information available? No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA115947782

Ethics

Also have a look at the ethics information for the parental line GEMi011-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line GEMi011-A.
Passage number reprogrammed P20

Reprogramming method

Vector type None

Vector free reprogramming

Type of used vector free reprogramming factor(s)
Protein
Protein

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Morphology pictures

Microbiology / Virus Screening

HIV 1 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: P26
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Presenilin 1 (PSEN1) mutations are the main cause of autosomal dominant Early-onset Alzheimer Disease (EOAD). Among them, deletions of exon 9 have been reported to be associated with a phenotype of spastic paraparesis.
Synonyms
  • AD
  • Alzheimer dementia
  • Alzheimer disease
  • Alzheimer's dementia
  • Alzheimer's disease
  • Alzheimers dementia
  • Alzheimers disease
  • presenile and senile dementia
  • Alzheimer disease, familial
show more synonyms
Genetic modifications
PSEN1 (target)
Gene knock-in
14q24.2
PSEN1
14q24.2
Design two sgRNAs at both ends of exon 9, combine with cas9 to cause cleavage, and get a cell line of exon9 deletion.
CRISPR-associated (CRISPR/Cas) System